|
|
Panel
Recommendation Options For
The Medical Device
Amendments to the Federal Food, Drug and Cosmetic Act (Act), as amended by the
Safe Medical Devices Act of 1990, allows the Food and Drug Administration to
obtain a recommendation from an expert advisory panel on designated medical
device premarket approval applications (PMAs) that are filed with the
Agency. The PMA must stand on its own
merits and your recommendation must be supported by safety and effectiveness
data in the application or by applicable publicly available information. Safety is defi
Your
recommendation options for the vote are as follows:
1.
APPROVAL – If there are no
conditions attached.
2.
APPROVABLE with
conditions – The panel may recommend
that the PMA be found approvable subject to specified conditions, such as
physician or patient education, labeling changes, or a further analysis of
existing data. Prior to voting, all of
the conditions should be discussed by the Panel.
3.
NOT APPROVABLE – The panel may
recommend that the PMA is not approvable if:
·
the data DO NOT provide a reasonable assurance that the device is
safe,
OR
·
the data DO NOT provide a reasonable assurance that the device is
effective, under the conditions of use prescribed, recommended, or suggested in
the proposed labeling.
·
Chair asks for a motion.
The motion can be either: (a) approval, (b) approvable with conditions, or (c)
not approvable.
·
A voting member makes a
motion recommending an action.
·
The Chair requests a second
on the motion.
·
The Chair entertains
discussion.
·
If the motion is for
approvable with conditions, then...
·
Chair asks for a motion for
an individual condition and a second.
·
The individual condition is
discussed.
·
The individual condition is
voted on by polling.
·
Additional conditions are
handled the same way.
·
The Chair calls for a vote
on the motion. If the motion is for
approvable with conditions, then the entire amended motion is voted on.
·
Voting is accomplished by
hand count polling.
·
After the voting is
complete, each panel member is asked to state for the record the rationale for
his/her vote. If the panel member voted
for disapproval, then he/she should indicate what is needed to make the PMA
approvable. The Consumer and Industry
Representatives also state their opinions at this time.
Note: PMA review is
INDEPENDENT of the following considerations:
·
Cost
·
Previous regulatory
difficulties
·
Clinical data submitted in
other PMAs for similar devices by competing companies
·
Medicolegal climate and its
effect on the standard of care